October 20, 2016
In a new study, treatment with the interleukin-1 inhibitor canakinumab had no significant effect on vascular function or structure compared with placebo in patients with atherosclerotic disease and type 2 diabetes or impaired glucose tolerance.
Researchers conducted a phase 2, double blind, randomized, placebo-controlled trial using MRI to evaluate the effects of canakinumab (Novartis) treatment, compared with placebo, on arterial function and structure. In total 189 patients with atherosclerotic disease and type 2 diabetes or impaired glucose tolerance at nine centers in Canada, Germany, Israel, the United Kingdom and the United States were enrolled. All patients were older than 80 years and more than 60% were men.